Patients with DDR1 HCC had lower DDR scores and benefited more from traditional treatment than patients with DDR2 HCC, which may be related to the low DDR activity, cell cycle activity and traditional drug resistance pathway activity in the DDR1 group. Here, DDR2 is linked to hepatocellular carcinoma.